Inhibikase Therapeutics, Inc. Cash and Restricted Cash
Inhibikase Therapeutics, Inc. (IKT) had Cash and Restricted Cash of $31.21 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31.21M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $49.57M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $139.22M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.27M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $31.21M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $49.57M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $139.22M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $38.27M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $77.74M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $73.44M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $56.49M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $913.42K 10-Q · filed 2025-11-14 |
| 2024-06-30 | $3.09M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $9.17M 10-K · filed 2026-03-26 |
| 2023-09-30 | $14.86M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $1.91M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $3.96M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $7.19M 10-K · filed 2025-03-27 |
| 2022-09-30 | $5.78M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $32.21M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $36.61M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $40.75M 10-K · filed 2024-03-27 |
| 2021-09-30 | $44.85M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $46.84M 10-Q · filed 2022-08-12 |
| 2021-03-31 | $9.61M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $13.95M 10-K · filed 2023-03-31 |
| 2020-09-30 | $16.17K 10-Q · filed 2021-11-15 |
| 2020-06-30 | $7.79K 10-Q · filed 2021-08-16 |
| 2020-03-31 | $13.14K 10-Q · filed 2021-05-17 |
| 2019-12-31 | $18.46K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |